# A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML

> **NCT03417427** · PHASE2 · UNKNOWN · sponsor: **Xuejie Jiang** · enrollment: 100 (estimated)

## Conditions studied

- Leukemia, Myeloid

## Interventions

- **DRUG:** Decitabine and Ara-C
- **DRUG:** Ara-C

## Key facts

- **NCT ID:** NCT03417427
- **Lead sponsor:** Xuejie Jiang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-02-01
- **Primary completion:** 2022-01-31
- **Final completion:** 2025-01-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03417427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03417427, "A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03417427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*